Recommendations Regarding Hyperglycaemia, Blood Pressure and Lipid Management in Diabetes Mellitus – Presentation of Key Aspects from the 2019 ESC/EASD Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases

1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz48610.1093/eurheartj/ehz48631497854Search in Google Scholar

2. Ryden L, Grant PJ, et.al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035308710.1093/eurheartj/eht108Search in Google Scholar

3. Piepoli MF, Hoes AW, et.al; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:23152381.10.1007/s12529-016-9583-6Search in Google Scholar

4. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017.Search in Google Scholar

5. Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res. 2017 Sep;40(9):795-806. doi: 10.1038/hr.2017.67. Epub 2017 Jul 13. PMID: 28701739.10.1038/hr.2017.6728701739Search in Google Scholar

6. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4:113–119.10.1111/j.1559-4572.2008.00044.x290159619614799Search in Google Scholar

7. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; Fourier Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:17131722.10.1056/NEJMoa1615664Search in Google Scholar

8. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; Odyssey Outcomes Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:20972107.10.1056/NEJMoa1801174Search in Google Scholar

9. Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C. Macrovascular Complications in Patients with Diabetes and Prediabetes. Biomed Res Int. 2017;2017:7839101. doi:10.1155/2017/783910110.1155/2017/7839101569739329238721Search in Google Scholar

10. Nagahisa T, Saisho Y. Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Ther. 2019;10(5):1733-1752. doi:10.1007/s13300-019-00680-510.1007/s13300-019-00680-5677857231440988Search in Google Scholar

11. Patel DK, Strong J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther. 2019;10(5):1771-1792. doi:10.1007/s13300-019-00686-z10.1007/s13300-019-00686-z677856331456166Search in Google Scholar

12. Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 2011 Dec; 17(38):4379-85. doi: 10.2174/138161211798999456. PMID: 22204436.10.2174/13816121179899945622204436Search in Google Scholar

13. American Diabetes Association, Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1)10.2337/dc20-S01331862756Search in Google Scholar